All Stories

  1. The effect of trauma‐focused therapy on voice‐hearing: An experience sampling study
  2. Experience sampling of suicidality, religiosity and spirituality in depression: Network analyses using dynamic time warping
  3. Van beschermd naar ondersteund wonen. Een visie op beschermd wonen en herstel
  4. Shaping Conditions for Recovery: A narrative on a Homeless Man with Severe Mental Illness in a Modern Welfare State
  5. The Experience Sampling Method: A New Way of Assessing Variability of the Emotional Dimensions of Religiosity and Spirituality in a Dutch Psychiatric Population
  6. Vital Needs of Dutch Homeless Service Users: Responsiveness of Local Services in the Light of Health Equity
  7. Positive affective recovery in daily life as a momentary mechanism across subclinical and clinical stages of mental disorder (Preprint)
  8. Positive affective recovery in daily life as a momentary mechanism across subclinical and clinical stages of mental disorder: Experience Sampling Study (Preprint)
  9. Factors That Influence the Use of Electronic Diaries in Health Care: Scoping Review
  10. Pre-training inter-rater reliability of clinical instruments in an international psychosis research project
  11. Health Patterns Reveal Interdependent Needs of Dutch Homeless Service Users
  12. Network dynamics of momentary affect states and future course of psychopathology in adolescents
  13. Dysregulated Lipid Metabolism Precedes Onset of Psychosis
  14. The Importance of Context: An ESM Study in Forensic Psychiatry
  15. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings
  16. Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
  17. Ecological momentary assessment versus retrospective assessment for measuring change in health-related quality of life following cardiac intervention
  18. Attachment as a framework to facilitate empowerment for people with severe mental illness
  19. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway
  20. Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis
  21. Early warning signals in psychopathology: what do they tell?
  22. A replication study of JTC bias, genetic liability for psychosis and delusional ideation
  23. Comparing psychotic experiences in low-and-middle-income-countries and high-income-countries with a focus on measurement invariance
  24. Monitoring risk assessment on an acute psychiatric ward: Effects on aggression, seclusion and nurse behaviour
  25. Qualitative analysis of clinicians’ perspectives on the use of a computerized decision aid in the treatment of psychotic disorders
  26. Ukrainian mental health services and World Psychiatric Association Expert Committee recommendations
  27. Introducing the DizzyQuest: an app-based diary for vestibular disorders
  28. Psychometric Properties of the Korean Version of the PsyMate Scale Using a Smartphone App: Ecological Momentary Assessment Study
  29. Lower emotional complexity as a prospective predictor of psychopathology in adolescents from the general population.
  30. The DizzyQuest: to have or not to have… a vertigo attack?
  31. Association of preceding psychosis risk states and non‐psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESIS‐2 cohort
  32. Polygenic risk score for schizophrenia was not associated with glycemic level (HbA1c) in patients with non-affective psychosis: Genetic Risk and Outcome of Psychosis (GROUP) cohort study
  33. Factors That Influence the Use of Electronic Diaries in Health Care: Scoping Review (Preprint)
  34. Expressive deficits and amotivation as mediators of the associations between cognitive problems and functional outcomes: Results from two independent cohorts
  35. The impact of emotion awareness and regulation on psychotic symptoms during daily functioning
  36. Digital assessment of working memory and processing speed in everyday life: Feasibility, validation, and lessons-learned
  37. Polygenic liability for schizophrenia and childhood adversity influences daily‐life emotion dysregulation and psychosis proneness
  38. Measuring resilience prospectively as the speed of affect recovery in daily life: a complex systems perspective on mental health
  39. An ecological momentary intervention incorporating personalised feedback to improve symptoms and social functioning in schizophrenia spectrum disorders
  40. Psychometric Properties of the Korean Version of the PsyMate Scale Using a Smartphone App: Ecological Momentary Assessment Study (Preprint)
  41. Parsing Psychology: Statistical and Computational Methods using Physiological, Behavioral, Social, and Cognitive Data
  42. A time-series network approach to auditory verbal hallucinations: Examining dynamic interactions using experience sampling methodology
  43. Childhood trauma and coping in patients with psychotic disorders and obsessive-compulsive symptoms and in un-affected siblings
  44. Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum
  45. Measuring within-day cognitive performance using the experience sampling method: A pilot study in a healthy population
  46. Implementing Experience Sampling Technology for Functional Analysis in Family Medicine – A Design Thinking Approach
  47. TwinssCan — Gene-Environment Interaction in Psychotic and Depressive Intermediate Phenotypes: Risk and Protective Factors in a General Population Twin Sample
  48. Recovery from daily-life stressors in early and chronic psychosis
  49. White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?
  50. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study
  51. Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study
  52. Identifying psychosis spectrum disorder from experience sampling data using machine learning approaches
  53. Evidence for interaction between genetic liability and childhood trauma in the development of psychotic symptoms
  54. Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling
  55. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study
  56. Childhood adversities and psychotic symptoms: The potential mediating or moderating role of neurocognition and social cognition
  57. Targeted Sequencing of 10,198 Samples Confirms Abnormalities in Neuronal Activity and Implicates Voltage-Gated Sodium Channels in Schizophrenia Pathogenesis
  58. The resource group method in severe mental illness: study protocol for a randomized controlled trial and a qualitative multiple case study
  59. Corrigendum to “Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder” [Schizophr. Res. 193 (2018) 173–181]
  60. The evidence‐based group‐level symptom‐reduction model as the organizing principle for mental health care: time for change?
  61. Smoking, symptoms, and quality of life in patients with psychosis, siblings, and healthy controls: a prospective, longitudinal cohort study
  62. Patterns of obsessive-compulsive symptoms and social functioning in schizophrenia; a replication study
  63. Potential Applications of Digital Technology in Assessment, Treatment, and Self-help for Hallucinations
  64. Functional recovery of individuals with serious mental illnesses: Development and testing of a new short instrument for routine outcome monitoring.
  65. Association Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis, Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up Study
  66. Long-term cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings
  67. Treatment results for severe psychiatric illness: which method is best suited to denote the outcome of mental health care?
  68. Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions
  69. The development and evaluation of a computerized decision aid for the treatment of psychotic disorders
  70. Reducing distress and improving social functioning in daily life in people with auditory verbal hallucinations: study protocol for the ‘Temstem’ randomised controlled trial
  71. Subjective quality of life in psychosis: Evidence for an association with real world functioning?
  72. Virtual-reality-based cognitive behavioural therapy versus waiting list control for paranoid ideation and social avoidance in patients with psychotic disorders: a single-blind randomised controlled trial
  73. Sensitivity to Peer Evaluation and Its Genetic and Environmental Determinants: Findings from a Population-Based Twin Study
  74. The role of cognitive functioning in the relationship between childhood trauma and a mixed phenotype of affective-anxious-psychotic symptoms in psychotic disorders
  75. An experience sampling study on the ecological validity of the SWN-20: Indication that subjective well-being is associated with momentary affective states above and beyond psychosis susceptibility
  76. Economic evaluation of an experience sampling method intervention in depression compared with treatment as usual using data from a randomized controlled trial
  77. Predicting Psychosis Using the Experience Sampling Method with Mobile Apps
  78. Constructing a Reward-Related Quality of Life Statistic in Daily Life—a Proof of Concept Study Using Positive Affect
  79. Network Approach to Understanding Emotion Dynamics in Relation to Childhood Trauma and Genetic Liability to Psychopathology: Replication of a Prospective Experience Sampling Analysis
  80. Demonstrating the reliability of transdiagnostic mHealth Routine Outcome Monitoring in mental health services using experience sampling technology
  81. The Latent Taxonicity of Schizotypy in Biological Siblings of Probands With Schizophrenia
  82. Familial liability to psychosis is a risk factor for multimorbidity in people with psychotic disorders and their unaffected siblings
  83. Is sensitivity to daily stress predictive of onset or persistence of psychopathology?
  84. White noise speech illusion and psychosis expression: An experimental investigation of psychosis liability
  85. Does the Social Functioning Scale reflect real-life social functioning? An experience sampling study in patients with a non-affective psychotic disorder and healthy control individuals
  86. The experience sampling method as an mHealth tool to support self-monitoring, self-insight, and personalized health care in clinical practice
  87. Psychological and Biological Validation of a Novel Digital Social Peer Evaluation Experiment (digi-SPEE)
  88. Exploring the use of Routine Outcome Monitoring in the treatment of patients with a psychotic disorder
  89. Autonomic Regulation and Auditory Hallucinations in Individuals With Schizophrenia: An Experience Sampling Study
  90. Evidence That the Impact of Childhood Trauma on IQ Is Substantial in Controls, Moderate in Siblings, and Absent in Patients With Psychotic Disorder
  91. Assertive community treatment and associations with delinquency
  92. Recurrent TRIO Fusion in Nontranslocation–Related Sarcomas
  93. Use of the experience sampling method in the context of clinical trials: Table 1
  94. A user-developed, user run recovery programme for people with severe mental illness: A randomised control trial
  95. Critical Slowing Down as a Personalized Early Warning Signal for Depression
  96. Change in daily life behaviors and depression: Within-person and between-person associations.
  97. Effects of momentary self-monitoring on empowerment in a randomized controlled trial in patients with depression
  98. Routine outcome measurement in the Netherlands – A focus on benchmarking
  99. Psychotic disorder and educational achievement: a family-based analysis
  100. Experience Sampling-Based Personalized Feedback and Positive Affect: A Randomized Controlled Trial in Depressed Patients
  101. Childhood trauma and childhood urbanicity in relation to psychotic disorder
  102. Flexible ACT & Resource-group ACT: Different Working Procedures Which Can Supplement and Strengthen Each Other. A Response
  103. Associations between Stereotype Awareness, Childhood Trauma and Psychopathology: A Study in People with Psychosis, Their Siblings and Controls
  104. Flexibility Index Test-60
  105. Measuring Health-Related Quality of Life by Experiences: The Experience Sampling Method
  106. Testing an mHealth Momentary Assessment Routine Outcome Monitoring Application: A Focus on Restoration of Daily Life Positive Mood States
  107. Evidence That Environmental and Genetic Risks for Psychotic Disorder May Operate by Impacting on Connections Between Core Symptoms of Perceptual Alteration and Delusional Ideation
  108. Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations
  109. Evidence that childhood urban environment is associated with blunted stress reactivity across groups of patients with psychosis, relatives of patients and controls
  110. Criminal Victimisation in People with Severe Mental Illness: A Multi-Site Prevalence and Incidence Survey in the Netherlands
  111. Stereotype Awareness, Self-Esteem and Psychopathology in People with Psychosis
  112. A therapeutic application of the experience sampling method in the treatment of depression: a randomized controlled trial
  113. Depression, subthreshold depression and comorbid anxiety symptoms in older Europeans: Results from the EURODEP concerted action
  114. Evidence That a Psychopathology Interactome Has Diagnostic Value, Predicting Clinical Needs: An Experience Sampling Study
  115. The distribution of self-reported psychotic-like experiences in non-psychotic help-seeking mental health patients in the general population; a factor mixture analysis
  116. Novel directions for psychiatric diagnosis: from psychopathology to motor function to monitoring technology
  117. Psychiatry beyond labels: introducingcontextual precision diagnosisacross stages of psychopathology
  118. Assertive Community Treatment and Associations with Substance Abuse Problems
  119. Beyond DSM and ICD: introducing “precision diagnosis” for psychiatry using momentary assessment technology
  120. FKBP5 as a possible moderator of the psychosis-inducing effects of childhood trauma
  121. Development of the Davos Assessment of Cognitive Biases Scale (DACOBS)
  122. Altered Transfer of Momentary Mental States (ATOMS) as the Basic Unit of Psychosis Liability in Interaction with Environment and Emotions
  123. Symptomatic remission in psychosis and real-life functioning
  124. Temporal dynamics of visual and auditory hallucinations in psychosis
  125. Daily life moment-to-moment variation in coping in people with a diagnosis of schizophrenia: state within trait psychosis
  126. The use of a Cumulative Needs for Care Monitor for individual treatment v. care as usual for patients diagnosed with severe mental illness, a cost-effectiveness analysis from the health care perspective
  127. Consumer-Providers in Assertive Community Treatment Programs: Associations With Client Outcomes
  128. A time-lagged momentary assessment study on daily life physical activity and affect.
  129. Childhood Trauma and Psychosis: A Case-Control and Case-Sibling Comparison Across Different Levels of Genetic Liability, Psychopathology, and Type of Trauma
  130. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: Evidence for a common genetic vulnerability?
  131. Emotional Experience in Negative Symptoms of Schizophrenia—No Evidence for a Generalized Hedonic Deficit
  132. Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports
  133. Momentary assessment technology as a tool to help patients with depression help themselves
  134. Function assertive community treatment (FACT) and psychiatric service use in patients diagnosed with severe mental illness
  135. Does monitoring need for care in patients diagnosed with severe mental illness impact on Psychiatric Service Use? Comparison of monitored patients with matched controls
  136. Assertive Community Treatment in the Netherlands: Outcome and Model Fidelity
  137. Neuroticism explained? From a non-informative vulnerability marker to informative person-context interactions in the realm of daily life
  138. Translating assessments of the film of daily life into person-tailored feedback interventions in depression
  139. Emotional Experience and Estimates of D2Receptor Occupancy in Psychotic Patients Treated With Haloperidol, Risperidone, or Olanzapine
  140. Cognitive deficits in nonaffective functional psychoses: A study in the Democratic Republic of Congo
  141. Experience sampling research in individuals with mental illness: reflections and guidance
  142. Social needs in daily life in adults with Pervasive Developmental Disorders
  143. Unveiling patterns of affective responses in daily life may improve outcome prediction in depression: A momentary assessment study
  144. Do depression and pain intensity interfere with physical activity in daily life in patients with Chronic Low Back Pain?
  145. Psychosis reactivity to cannabis use in daily life: an experience sampling study
  146. Systematic monitoring of needs for care and global outcomes in patients with severe mental illness
  147. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial
  148. Meeting risk with resilience: high daily life reward experience preserves mental health
  149. Transition from stress sensitivity to a depressive state: longitudinal twin study
  150. Depression and parkinsonism in older Europeans: results from the EURODEP concerted action
  151. The cumulative needs for care monitor: a unique monitoring system in the south of the Netherlands
  152. Concurrent Measurement of "Real-World" Stress and Arousal in Individuals With Psychosis: Assessing the Feasibility and Validity of a Novel Methodology
  153. Capturing coping with symptoms in people with a diagnosis of schizophrenia: introducing the MACS-24
  154. Experience sampling research in psychopathology: opening the black box of daily life
  155. Are social phobia and paranoia related, and which comes first?
  156. COMT Val158Met moderation of cannabis-induced psychosis: a momentary assessment study of ‘switching on’ hallucinations in the flow of daily life
  157. Momentary assessment research in psychosis.
  158. A real-life observational study of the effectiveness of FACT in a Dutch mental health region
  159. Mechanisms of gene–environment interactions in depression: evidence that genes potentiate multiple sources of adversity
  160. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness–persistence–impairment model of psychotic disorder
  161. Executive function does not predict coping with symptoms in stable patients with a diagnosis of schizophrenia
  162. Susceptibility to Depression Expressed as Alterations in Cortisol Day Curve: A Cross-Twin, Cross-Trait Study
  163. Subjective Experience of Cognitive Failures as Possible Risk Factor for Negative Symptoms of Psychosis in the General Population
  164. The psychology of psychiatric genetics: Evidence that positive emotions in females moderate genetic sensitivity to social stress associated with the BDNF Val⁶⁶Met polymorphism.
  165. The use of the Camberwell Assessment of Need in treatment: what unmet needs can be met?
  166. Genetic risk of depression and stress-induced negative affect in daily life
  167. The Catechol-O-Methyl Transferase Val158Met Polymorphism and Experience of Reward in the Flow of Daily Life
  168. The association between cognition and functional outcome in first-episode patients with schizophrenia: mystery resolved?
  169. The dynamics of symptomatic and non-symptomatic coping with psychotic symptoms in the flow of daily life
  170. Evidence that moment-to-moment variation in positive emotions buffer genetic risk for depression: a momentary assessment twin study
  171. The relationship between cognitive dysfunction and stress sensitivity in schizophrenia
  172. An observational, “real life” trial of the introduction of assertive community treatment in a geographically defined area using clinical rather than service use outcome criteria
  173. A momentary assessment study of the relationship between affective and adrenocortical stress responses in daily life
  174. Premorbid IQ as a predictor for the course of IQ in first onset patients with schizophrenia: A 10-year follow-up study
  175. The Role of Gender Differences and Other Client Characteristics in the Prevalence of DSM-IV Affective Disorders Among a European Therapeutic Community Population
  176. Validation of Remission Criteria for Schizophrenia
  177. Computerized experience sampling method (ESMc): Assessing feasibility and validity among individuals with schizophrenia
  178. Genes Making One Feel Blue in the Flow of Daily Life: A Momentary Assessment Study of Gene-Stress Interaction
  179. Evidence for instrument and family-specific variation of subclinical psychosis dimensions in the general population.
  180. Diurnal mood variation in major depressive disorder.
  181. Hospital comorbidity bias and the concept of schizophrenia
  182. Physical health and depressive symptoms in older Europeans
  183. Subtle Fluctuations in Psychotic Phenomena as Functional States of Abnormal Dopamine Reactivity in Individuals at Risk
  184. Behavioural sensitization to daily life stress in psychosis
  185. Do different psychotic experiences differentially predict need for care in the general population?
  186. Electronic monitoring of salivary cortisol sampling compliance in daily life
  187. The schizophrenia envirome
  188. Early adolescent cannabis exposure and positive and negative dimensions of psychosis